CASI Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
CASI Pharmaceuticals's earnings have been declining at an average annual rate of -1.4%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 51.9% per year.
Key information
-1.4%
Earnings growth rate
9.0%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 51.9% |
Return on equity | -78.7% |
Net Margin | -95.6% |
Next Earnings Update | 01 Apr 2024 |
Recent past performance updates
Recent updates
Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%
Mar 12CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%
Dec 18We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate
Sep 02Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?
May 20Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M
Sep 23CASI Pharmaceuticals Q2 2022 Earnings Preview
Aug 11Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?
May 26Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts
Aug 14Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?
May 25Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?
Mar 16Companies Like CASI Pharmaceuticals (NASDAQ:CASI) Are In A Position To Invest In Growth
Feb 18How Much Of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Do Insiders Own?
Jan 23Is CASI Pharmaceuticals' (NASDAQ:CASI) 205% Share Price Increase Well Justified?
Dec 28CASI Pharma's CD19 CAR-T nabs accelerated review in China for a type of blood cancer
Dec 23CASI Pharmaceuticals appoints Weihao Xu as CFO
Dec 16Growth Investors: Industry Analysts Just Upgraded Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Revenue Forecasts By 4.3%
Dec 02The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Wei-Wu He, Just Bought 4.7% More Shares
Nov 27Casi Pharmaceuticals jumps 6% after CEO buys 227.5K shares
Nov 25Juventas initiates registration study for CNCT19
Nov 19CASI Pharmaceuticals EPS misses by $0.08, beats on revenue
Nov 09Revenue & Expenses BreakdownBeta
How CASI Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 23 | 42 | -40 | 42 | 12 |
30 Jun 23 | 44 | -41 | 42 | 13 |
31 Mar 23 | 42 | -38 | 39 | 15 |
31 Dec 22 | 43 | -41 | 38 | 16 |
30 Sep 22 | 37 | -27 | 39 | 16 |
30 Jun 22 | 35 | -32 | 39 | 15 |
31 Mar 22 | 33 | -31 | 39 | 13 |
31 Dec 21 | 30 | -37 | 38 | 14 |
30 Sep 21 | 26 | -45 | 35 | 14 |
30 Jun 21 | 22 | -52 | 34 | 14 |
31 Mar 21 | 17 | -54 | 30 | 14 |
31 Dec 20 | 15 | -48 | 27 | 11 |
30 Sep 20 | 12 | -47 | 27 | 10 |
30 Jun 20 | 10 | -40 | 29 | 9 |
31 Mar 20 | 8 | -46 | 30 | 10 |
31 Dec 19 | 4 | -46 | 30 | 9 |
30 Sep 19 | 3 | -43 | 27 | 11 |
30 Jun 19 | 0 | -42 | 25 | 11 |
31 Mar 19 | 0 | -32 | 22 | 10 |
31 Dec 18 | 0 | -27 | 18 | 9 |
30 Sep 18 | 0 | -23 | 14 | 9 |
30 Jun 18 | 0 | -16 | 7 | 8 |
31 Mar 18 | 0 | -13 | 4 | 8 |
31 Dec 17 | 0 | -11 | 4 | 7 |
30 Sep 17 | 0 | -8 | 4 | 5 |
30 Jun 17 | 0 | -8 | 4 | 5 |
31 Mar 17 | 0 | -9 | 5 | 4 |
31 Dec 16 | 0 | -9 | 5 | 4 |
30 Sep 16 | 0 | -8 | 4 | 4 |
30 Jun 16 | 0 | -8 | 4 | 4 |
31 Mar 16 | 0 | -7 | 3 | 4 |
31 Dec 15 | 0 | -7 | 4 | 4 |
30 Sep 15 | 0 | -7 | 4 | 3 |
30 Jun 15 | 0 | -27 | 4 | 3 |
31 Mar 15 | 0 | -27 | 4 | 3 |
31 Dec 14 | 0 | -26 | 4 | 3 |
30 Sep 14 | 0 | -26 | 4 | 2 |
30 Jun 14 | 0 | -6 | 3 | 2 |
31 Mar 14 | 0 | -6 | 3 | 3 |
31 Dec 13 | 0 | -6 | 3 | 3 |
30 Sep 13 | 1 | -5 | 3 | 2 |
30 Jun 13 | 1 | -5 | 3 | 2 |
31 Mar 13 | 1 | -13 | 2 | 2 |
Quality Earnings: CASI is currently unprofitable.
Growing Profit Margin: CASI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CASI is unprofitable, and losses have increased over the past 5 years at a rate of 1.4% per year.
Accelerating Growth: Unable to compare CASI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CASI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: CASI has a negative Return on Equity (-78.73%), as it is currently unprofitable.